Herpesin (Aciclovir)

Herpesin is indicated for the treatment of several herpes virus infections, as determined by a healthcare professional.

• Herpes simplex virus infections (e.g., oral cold sores)
• Genital herpes infections
• Herpes zoster (shingles) episodes
• Varicella (chickenpox) in susceptible individuals
• Suppression of recurrent herpes outbreaks
• Post‑exposure prophylaxis in immunocompromised patients

• Aciclovir, the active component of Herpesin, is a nucleoside analogue that is selectively phosphorylated by viral thymidine kinase. The resulting triphosphate form competitively inhibits viral DNA polymerase, leading to premature chain termination and preventing synthesis of viral DNA. This action limits viral replication in infected cells while having minimal effect on host cellular DNA processes.

Adverse reactions to Herpesin can vary in frequency and severity.

Common

• Headache
• Nausea or vomiting
• Diarrhea
• Mild skin rash
• Fatigue

Serious

• Acute renal failure, especially with dehydration
• Severe allergic reactions (e.g., Stevens‑Johnson syndrome)
• Hematologic abnormalities such as neutropenia
• Hepatic dysfunction
• Central nervous system effects (e.g., confusion, seizures)

When prescribing Herpesin, clinicians should consider several safety factors.

• Assess renal function before initiating therapy and adjust dose in impaired patients.
• Monitor for signs of hypersensitivity, especially skin eruptions.
• Use caution in patients with a history of seizures or neurological disorders.
• Evaluate liver function in individuals with pre‑existing hepatic disease.
• Advise adequate hydration to reduce the risk of renal complications.
• Discuss potential interactions with other nephrotoxic or ototoxic drugs.
• Pregnant or breastfeeding patients should be managed according to current clinical guidelines.

Herpesin may interact with other medications, influencing efficacy or safety.

Avoid

• Concomitant use of nephrotoxic agents such as aminoglycosides or non‑steroidal anti‑inflammatory drugs (NSAIDs) without monitoring.
• Co‑administration with probenecid, which can increase aciclovir plasma concentrations.
• Simultaneous use of other antiviral nucleoside analogues that share renal excretion pathways.

Use with caution

• Cimetidine, which may reduce renal clearance of aciclovir.
• Immunosuppressants (e.g., cyclosporine) that could alter infection risk.
• Warfarin, as occasional alterations in INR have been reported.
• Oral contraceptives, although significant effects are uncommon, monitoring is advised.